Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 7 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

822 CYT X300, a novel EGFR x pan-gamma delta T cell engager for the treatment of solid tumors

  • Domenico Mavilio1
  • Valentina Cazzetta2
  • Joanna Mikulak2
  • Roseanna Hare3
  • James W Legg4
  • Mark Uden4
  • Robert Good4
  • Julie Hoong4
  • Aleksandra Laskowska4
  • Fevzi Demircioglu4
  • Shauna Corcoran4
  • Luke Cave4
3 more authors
  • Carlotta Cattolico4
  • Leia Griffin4
  • Natalie Mount4
4 affiliations
  1. 1Aff3 grid.417728.f0000000417568807Unit of Clinical and Experimental ImmunologyHumanitas Clinical and Research Center Rozzano Milan Italy
  2. 2Laboratory of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
  3. 31Pear Bio, London, UK
  4. 4Cytospire Therapeutics, London, UK
Open at sourcePDFDOICite

Related

  1. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
    Bonnevaux H, Guerif S, Albrecht J +11
    OncoImmunologyPeer-reviewedCC BY-NCFull text16 citedMedical imaging & radiologyHAL
  2. 53L10 T-cell engager tribody for immunotherapy of multiple solid tumors
    Margherita Passariello, Martina Belardo, Toshikazu Inoue +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  3. Local T-cell engager secretion reprograms endogenous antitumor immunity and enhances CAR-T cell persistence in solid tumors
    Javier Arroyo-Ródenas, Alex Chen, Jason Tonne +15
    Journal for Immunotherapy of CancerPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  4. MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
    Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger +24
    Nature MedicinePeer-reviewedCC BY-NC-NDFull text8 citedOncologyOpenAlex
  5. 891 Pre-clinical development of a best-in-class bispecific T cell engager targeting a highly abundant peptide for the treatment of melanoma
    Samuel Ward, David Cook, Xiaoyan Pan +32
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{mavilio2026x300,
  title = {{822 CYT X300, a novel EGFR x pan-gamma delta T cell engager for the treatment of solid tumors}},
  author = {Domenico Mavilio and Valentina Cazzetta and Joanna Mikulak and Roseanna Hare and James W Legg and Mark Uden and Robert Good and Julie Hoong and Aleksandra Laskowska and Fevzi Demircioglu and Shauna Corcoran and Luke Cave and Carlotta Cattolico and Leia Griffin and Natalie Mount},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0822},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0822},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 822 CYT X300, a novel EGFR x pan-gamma delta T cell engager for the treatment of solid tumors
AU  - Domenico Mavilio
AU  - Valentina Cazzetta
AU  - Joanna Mikulak
AU  - Roseanna Hare
AU  - James W Legg
AU  - Mark Uden
AU  - Robert Good
AU  - Julie Hoong
AU  - Aleksandra Laskowska
AU  - Fevzi Demircioglu
AU  - Shauna Corcoran
AU  - Luke Cave
AU  - Carlotta Cattolico
AU  - Leia Griffin
AU  - Natalie Mount
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0822
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0822
SN  - 2051-1426
ER  -